Edition:
India

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

4.00USD
7 Feb 2020
Change (% chg)

$0.01 (+0.25%)
Prev Close
$3.99
Open
$4.00
Day's High
$4.01
Day's Low
$4.00
Volume
268,750
Avg. Vol
295,251
52-wk High
$14.45
52-wk Low
$2.43

Latest Key Developments (Source: Significant Developments)

Diplomat Appoints Daniel Davison As CFO
Friday, 15 Mar 2019 

March 15 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT APPOINTS DANIEL DAVISON AS CHIEF FINANCIAL OFFICER.DIPLOMAT PHARMACY INC - DAVISON SUCCEEDING ATUL KAVTHEKAR.DIPLOMAT PHARMACY - KAVTHEKAR WILL REMAIN WITH CO THROUGH BRIEF PERIOD TO ENSURE SMOOTH TRANSITION OF RESPONSIBILITIES.DIPLOMAT PHARMACY INC - DAVISON'S APPOINTMENT IS EFFECTIVE APRIL 8.  Full Article

Diplomat Pharmacy Inc Files For Non-Timely 10-K
Tuesday, 5 Mar 2019 

March 4 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT PHARMACY INC FILES FOR NON-TIMELY 10-K- SEC FILING.DIPLOMAT PHARMACY - RECENTLY DETERMINED NEED TO RECORD SIGNIFICANT NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS.DIPLOMAT PHARMACY - SIGNIFICANT NON-CASH IMPAIRMENT CHARGE RELATED TO GOODWILL, DEFINITE-LIVED INTANGIBLE ASSETS , WILL MATERIALLY IMPACT Q4 RESULTS.DIPLOMAT PHARMACY - NEEDS TIME TO FINALIZE LEVEL OF IMPAIRMENT FOR GOODWILL AND THE DEFINITE-LIVED INTANGIBLE ASSETS, TAX IMPLICATIONS, IMPACT ON Q4.  Full Article

Diplomat Delays Release Of 2018 Financial Results And Filing Of 10-K
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Diplomat Pharmacy Inc ::DIPLOMAT DELAYS RELEASE OF 2018 FINANCIAL RESULTS AND FILING OF 10-K.DIPLOMAT PHARMACY INC - WILL PROVIDE UPDATED OUTLOOK WHEN IT REPORTS 2018 RESULTS..DIPLOMAT PHARMACY INC - COMPANY WITHDRAWS 2019 FULL YEAR PRELIMINARY OUTLOOK PROVIDED IN JANUARY.DIPLOMAT PHARMACY INC - COMPANY EXPECTS TO FILE ITS ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED DECEMBER 31, 2018 SOON AFTERWARDS..DIPLOMAT PHARMACY INC - WILL NEED TO RECORD A NON-CASH IMPAIRMENT CHARGE RELATED TO ITS PBM BUSINESS..DIPLOMAT PHARMACY INC - CHARGE IS EXPECTED TO BE EQUAL TO A SIGNIFICANT PORTION OF PBM'S GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS.DIPLOMAT PHARMACY INC - JANUARY RESULTS HAVE COME IN SIGNIFICANTLY BELOW EXPECTATIONS.DIPLOMAT PHARMACY - PBM'S GOODWILL AND DEFINITE-LIVED INTANGIBLE ASSETS TOTALED ABOUT $630 MILLION AS OF DECEMBER 31, 2018, PRIOR TO IMPAIRMENT CHARGES.DIPLOMAT PHARMACY INC - NOTIFIED OF ADDITIONAL CUSTOMER LOSSES IN ITS PBM BUSINESS SINCE EARLY JANUARY.DIPLOMAT PHARMACY INC - CHARGE RELATES TO 2017 ACQUISITIONS OF NPS AND LDI AND IS DRIVEN BY REDUCED FINANCIAL FORECASTS FOR PBM BUSINESS..DIPLOMAT PHARMACY INC - FULL-YEAR 2018 REVENUES AND TOTAL ADJUSTED EBITDA ARE NOT IMPACTED BY ANY IMPAIRMENT CHARGE.DIPLOMAT PHARMACY INC - OBSERVING INCREASED COMPETITIVE PRESSURE IN SPECIALTY MARKET, DRIVING A REDUCED OUTLOOK FOR SCRIPT VOLUMES IN 2019.  Full Article

No consensus analysis data available.